E.E. Geduld’s Arcturus Therapeutics ARCT Stock Holding History

E.E. Geduld’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-1,429	Closed	-$154K	–	249
2014 Q3	$154K	Sell	1,429 -714	-33%	-$93K	0.11%	160
2014 Q2	$260K	Sell	2,143 -1,428	-40%	-$172K	0.16%	152
2014 Q1	$454K	Buy	3,571 +714	+25%	+$106K	0.25%	110
2013 Q4	$360K	Buy	2,857 +1,428	+100%	+$179K	0.17%	134
2013 Q3	$180K	Buy	+1,429	New	+$127K	0.11%	185

Other funds holding ARCT

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

LCM

Leisure Capital Management Costa Mesa, California $320M AUM 39.11% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

E.E. Geduld's ARCT Position: Q4 2014 in Review

E.E. Geduld sold out of Arcturus Therapeutics (ARCT) in Q4 2014, closing a stake of 1,429 shares — an estimated $154K sold.

E.E. Geduld first reported a position in ARCT in Q3 2013 and held it in 5 quarters. The position peaked at $454K in Q1 2014. 28 funds tracked by Wall St. Rank hold ARCT as of Q4 2014.

E.E. Geduld reported no remaining Arcturus Therapeutics position as of Q4 2014 after selling out during the quarter.
E.E. Geduld sold 1,429 Arcturus Therapeutics shares in Q4 2014, an estimated $154K.
E.E. Geduld first reported a position in Arcturus Therapeutics in Q3 2013 and held it in 5 quarters.
E.E. Geduld's Arcturus Therapeutics position peaked at $454K in Q1 2014.
28 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2014.

Based on E.E. Geduld's 13F filing for Q4 2014, filed 30 Jan 2015.